unknown
Stage
About
Endeavor BioMedicines is a clinical-stage biotechnology company developing therapeutics targeting the Hedgehog signaling pathway, with a lead candidate, taladegib (ENV-101), in clinical trials for treating fibrotic lung diseases such as idiopathic pulmonary fibrosis.
Explore Endeavor BioMedicines's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.